Phase 3 zanubrutinib (BGB-3111) vs bendamustine plus rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Conference Proceedings

Peter Hillmen, Jennifer R Brown, Brad S Kahl, Paolo Ghia, Tadeusz Robak, Carol Marimpietri, Aileen Cohen, Jane Huang, Constantine Si Lun Tam

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2018